Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease

Journal of Virology

Volumn 90, Issue 1, 2016, Pages 57-67

  Tao, Xinrong ^a   Garron, Tania ^a   Agrawal, Anurodh Shankar ^a   Algaissi, Abdullah ^a,e   Peng, Bi Hung ^a   Wakamiya, Maki ^b   Chan, Teh Sheng ^a   Lu, Lu ^c   Du, Lanying ^d   Jiang, Shibo ^d   Couch, Robert B ^a   Tseng, Chien Te K ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c FUDAN UNIVERSITY   (China)

^d NEW YORK BLOOD CENTER   (United States)

^e JAZAN UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL PEPTIDASE IV; NEUTRALIZING ANTIBODY; VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BRAIN INFECTION; BRAIN STEM; CONTROLLED STUDY; CORONAVIRUS INFECTION; DISEASE MODEL; DISEASE SEVERITY; DRUG RESEARCH; HISTOPATHOLOGY; ID50; INFLAMMATORY INFILTRATE; LD50; LUNG PARENCHYMA; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ANIMAL; ANIMAL STRUCTURES; BLOOD; BRAIN; CORONAVIRUS INFECTIONS; CYTOCHEMISTRY; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LIVER; LUNG; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BRAIN; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HISTOCYTOCHEMISTRY; HUMANS; LETHAL DOSE 50; LIVER; LUNG; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84953931577     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02009-15     Document Type: Article

References (36)

1. Peiris JS, Guan Y, Yuen KY. 2004. Severe acute respiratory syndrome. Nat Med 10:S88-97. http://dx.doi.org/10.1038/nm1143.
2. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA. 2013. Hospital outbreak of Middle East respiratory syndrome coronavirus. NEngl JMed369:407-416. http://dx.doi.org/10.1056/NEJMoa1306742.
3. Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu D, Fontanet A, van der Werf S. 2013. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 381:2265-2272. http://dx.doi.org/10.1016/S0140-6736(13)60982-4.
4. World Health Organization. 3 June 2015. Summary and risk assessment of current situation in Korea and China. MERS-CoV risk assessment. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-3june2015/en/.
5. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, Fischer ER, Martellaro C, Okumura A, Chang J, Scott D, Benecke AG, Katze MG, Feldmann H, Munster VJ. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 110:16598-16603. http://dx.doi.org/10.1073/pnas.1310744110.
6. Falzarano D, de Wit E, Feldmann F, Rasmussen AL, Okumura A, Peng X, Thomas MJ, van Doremalen N, Haddock E, Nagy L, LaCasse R, Liu T, Zhu J, McLellan JS, Scott DP, Katze MG, Feldmann H, Munster VJ. 2014. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 10:e1004250. http://dx.doi.org/10.1371/journal.ppat.1004250.
7. Coleman CM, Matthews KL, Goicochea L, Frieman MB. 2014. Wildtype and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 95:408-412. http://dx.doi.org/10.1099/vir.0.060640-0.
8. de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T, Lackemeyer MG, Martellaro C, Milne-Price S, Haddock E, Haagmans BL, Feldmann H, Munster VJ. 2013. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One 8:e69127. http://dx.doi.org/10.1371/journal.pone.0069127.
9. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Ouwendijk WJ, Bestebroer TM, Spronken MI, van Amerongen G, Rottier PJ, Fouchier RA, Bosch BJ, Osterhaus AD, Haagmans BL. 2014. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 88:1834-1838. http://dx.doi.org/10.1128/JVI.02935-13.
10. Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS, Couch RB, Tseng CT. 2015. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 89: 3659-3670. http://dx.doi.org/10.1128/JVI.03427-14.
11. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB, Kyratsous CA. 2015. Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad SciUS A 112:8738-8743. http://dx.doi.org/10.1073/pnas.1510830112.
12. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Gale MJ, Jr, Baric RS, Enjuanes L, Gallagher T, McCray PB, Jr, Perlman S. 2014. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 111:4970-4975. http://dx.doi.org/10.1073/pnas.1323279111.
13. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, Jiang S. 2013. A truncated receptor-binding domain of MERSCoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587. http://dx.doi.org/10.1371/journal.pone.0081587.
14. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7:e35421. http://dx.doi.org/10.1371/journal.pone.0035421.
15. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. 2014. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 32:6170-6176. http://dx.doi.org/10.1016/j.vaccine.2014.08.086.
16. Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, Tao X, Tasneem S, Lu L, Tseng CT, Zhou Y, Perlman S, Jiang S, Du L. 2 February 2015, posting date. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol http://dx.doi.org/10.1038/cmi.2015.03.
17. Tao X, Mei F, Agrawal A, Peters CJ, Ksiazek TG, Cheng X, Tseng CT. 2014. Blocking of exchange proteins directly activated by cAMP leads to reduced replication of Middle East respiratory syndrome coronavirus. J Virol 88:3902-3910. http://dx.doi.org/10.1128/JVI.03001-13.
18. Channappanavar R, Lu L, Xia S, Du L, Meyerholz DK, Perlman S, Jiang S. 8 June 2015, posting date. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis http://dx.doi.org/10.1093/infdis/jiv325.
19. Tang J, Zhang N, Tao X, Zhao G, Guo Y, Tseng CT, Jiang S, Du L, Zhou Y. 2015. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 11: 1244-1250. http://dx.doi.org/10.1080/21645515.2015.1021527.
20. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. 2015. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 6:7712. http://dx.doi.org/10.1038/ncomms8712.
21. Gao J, Lu G, Qi J, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF. 2013. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 87:13134-13140. http://dx.doi.org/10.1128/JVI.02433-13.
22. Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, Wang Q, Chan JF, Du L, Yu F, Ma C, Ye S, Yuen KY, Zhang R, Jiang S. 2014. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 5:3067.
23. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. http://dx.doi.org/10.1056/NEJMoa1211721.
24. Zumla A, Hui DS, Perlman S. 3 June 2015, posting dateMiddle East respiratory syndrome. Lancet http://dx.doi.org/10.1016/S0140-6736(15)60454-8.
25. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, Muller MA, Haas W, Guberina H, Rohnisch T, Schmid-Wendtner M, Aldabbagh S, Dittmer U, Gold H, Graf P, Bonin F, Rambaut A, Wendtner CM. 2013. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13:745-751. http://dx.doi.org/10.1016/S1473-3099(13)70154-3.
26. Gorrell MD. 2005. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 108:277-292. http://dx.doi.org/10.1042/CS20040302.
27. Denison MR. 2004. Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Pediatr Infect Dis J 23: S207-S214. http://dx.doi.org/10.1097/01.inf.0000144666.95284.05.
28. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. 2004. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 203:622-630. http://dx.doi.org/10.1002/path.1560.
29. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS. 2003. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773-1778. http://dx.doi.org/10.1016/S0140-6736(03)13413-7.
30. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS. 2005. Multiple organ infection and the pathogenesis of SARS. J Exp Med 202:415-424. http://dx.doi.org/10.1084/jem.20050828.
31. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, Li Z, Deng P, Zhang J, Zhong N, Ding Y, Jiang Y. 2005. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis 41:1089-1096. http://dx.doi.org/10.1086/444461.
32. McCray PB, Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, Netland J, Jia HP, Halabi C, Sigmund CD, Meyerholz DK, Kirby P, Look DC, Perlman S. 2007. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 81:813-821. http://dx.doi.org/10.1128/JVI.02012-06.
33. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3:e5. http://dx.doi.org/10.1371/journal.ppat.0030005.
34. Tseng CT, Huang C, Newman P, Wang N, Narayanan K, Watts DM, Makino S, Packard MM, Zaki SR, Chan TS, Peters CJ. 2007. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor. J Virol 81:1162-1173. http://dx.doi.org/10.1128/JVI.01702-06.
35. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, Saeed BT, Wahbi A, Saedy A, AlDabbagh T, Okaili R, Sadat M, Balkhy H. 20 January 2015, posting dateSevere neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection http://dx.doi.org/10.1007/s15010-015-0720-y.
36. Al-Tawfiq JA. 2013. Middle East respiratory syndrome-coronavirus infection: an overview. J Infect Public Health 6:319-322. http://dx.doi.org/10.1016/j.jiph.2013.06.001.